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Abstract Despite the growing understanding of the mech-
anisms of carcinogenesis, cancers of the central nervous
system are usually associated with unfavorable prognosis.
The use of an appropriate molecular marker may improve
the treatment outcome by allowing early diagnosis and
treatment susceptibility monitoring. Since methylation of
tumor-derived DNA can be detected in the serum of cancer
patients, this makes DNA methylation-based biomarkers
one of the most promising diagnostic strategies. In this
study, the methylation profiles of MGMT, RASSF1A,
p15INK4B, and p14ARF genes were evaluated in serum
free-circulating DNA and the corresponding tumor tissue
in a group of 33 primary or metastatic central nervous
system cancer patients. Gene promoter methylation was
assessed using methylation-specific polymerase chain reac-
tion (PCR). All the tested genes were found to be methylat-
ed to a different extent in both serum and tumor samples. In
comparison to metastatic brain tumor patients, the patients
with glial tumors were characterized by a higher frequency
of gene hypermethylation. The hypermethylation of
RASSF1A differentiated primary from metastatic brain can-
cers. Moreover, the gene methylation profiles observed in
serum, in most cases, matched the methylation profiles
detected in paired tumor samples.
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Introduction
It is widely accepted that the deregulation of cellular
homeostasis observed in cancer cells may be a conse-
quence of the aberrations in the epigenetic information
besides genetic mutations (Kulis and Esteller 2010).
Epigenetic mechanisms are responsible for the regulation
of gene expression and their frequent changes in carci-
nogenesis are especially attractive for investigation because of
their potential applicability in both tumor diagnostics and
therapy. The hypermethylation of CpG islands in the promoter
regions of tumor suppressor genes, which leads to their si-
lencing, can be found at all stages of carcinogenesis. The
profile of DNA methylation changes is claimed to be relative-
ly specific for tumor (sub)type, which makes it a promising
biomarker for disease detection and stratification. Evidence
shows that it may be also used for both prognostic and
predictive purposes (Paluszczak and Baer-Dubowska 2006).
Central nervous system (CNS) cancers are usually highly
malignant, chemo- and radio-resistant, and difficult to cure
by surgical resection. The most common brain cancers of
adults are gliomas, with glioblastoma (GBM) being the most
common and most aggressive. Despite advances in neuro-
imaging, neurosurgery, and chemotherapy, the survival time
of GBM patients very rarely exceeds 2 years, and the me-
dian survival time is only about 12 months (Johnson et al.
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2012). The observation that the hypermethylation ofMGMT
may be a good predictive factor of the response of CNS
cancer patients to alkylating anti-cancer drugs, especially
temozolomide, led to attempts of clinical application of
epigenetic diagnostics (Esteller et al. 2000; Hegi et al.
2004, 2005). The specificity of the predictive testing of
MGMT methylation is, however, sometimes questioned,
since this drug resistance phenotype may also depend on
other molecular changes (McEllin et al. 2010; Zhang et al.
2010). The elaboration of a diagnostic gene panel including
MGMT could potentially improve clinical validity. Apart
from MGMT, DNA methylation changes in CNS tumors
also affect other genes, especially tumor suppressors, such
as RASSF1A, p15INK4B, or p14ARF (Lorente et al. 2009;
Mulholland et al. 2012; Riemenschneider et al. 2010; Wolter
et al. 2001). Their silencing is one of the mechanisms which
finally lead to uncontrolled cell proliferation and evading
apoptosis and, subsequently, to the acquisition of an aggres-
sive phenotype. Hypermethylation of those genes was found
to be involved not only in the carcinogenesis of the CNS
tissues, but also breast (Buyru et al. 2009; Fiegl et al. 2005;
Sharma et al. 2007) or lung (Furonaka et al. 2004; Ramirez
et al. 2003) and in malignant melanoma (Freedberg et al.
2008; Tellez et al. 2009). Such solid tumors often metasta-
size to the brain and it is thought that DNA methylation
changes may be responsible for the acquisition of cerebral
metastatic potential by those cells. Metastases are the most
common tumors of the CNS, and lung carcinoma, melano-
ma, and breast carcinoma are the primary tumors most
frequently involved in brain invasion (Gavrilovic and
Posner 2005; Gonzalez-Gomez et al. 2004).
Because of the limitations in the accessibility of CNS
tumor tissue for diagnostic purposes, other sources of
tumor-derived DNA are in high demand. There is evidence
that significantly higher levels of free-circulating DNA are
present in the serum of solid tumor patients and it is believed
that most of this DNA is derived from tumor cells (Fiegl et
al. 2005; Fleischhacker and Schmidt 2007). Although CNS
tumors may shed free DNA into the extracellular space at
the same rate as systematic tumors, several anatomic and
physiologic differences make it uncertain as to how much of
this DNA may reach systematic circulation. Primary CNS
tumors are confined to the cranial vault, where their extra-
cellular space drains largely into the cerebrospinal fluid
(CSF), which, following circulation, will eventually clear
into the bloodstream. This sink effect of the CSF may
substantially dilute the amount of detectable circulating
nucleic acids in the blood samples of patients with CNS
tumors (Lavon et al. 2010).
So far, only a few studies have evaluated the levels of
free-circulating DNA in CNS neoplasms in the context of
the detection of gene promoter methylation (Lavon et al.
2010; Wakabayashi et al. 2009; Weaver et al. 2006).
Moreover, different protocols for sample collection and
circulating DNA assessment were used in these studies,
and a limited number of gene promoters was evaluated.
Since the quantity of free-circulating DNA found in serum
is low, the use of an appropriate method of DNA extraction
is of high importance. As a result of the comparison of
different methods of isolation of DNA from the serum of
colorectal cancer patients, Fong et al. (2009) proposed that
the sodium iodide protocol is the best option.
In this study, we compared the profile of aberrant meth-
ylation of MGMT, RASSF1A, p15INK4B, and p14ARF
genes in serum free-circulating DNA and corresponding
tumor tissue in a group of CNS cancer patients. MGMT,
the O6-methylguanine-DNA methyltransferase gene, is lo-
cated at chromosome 10q26 and encodes a DNA repair
enzyme that can abrogate the effects of alkylating chemother-
apy, such as temozolomide. RASSF1A encodes a Ras associ-
ation domain family member 1 protein, which interacts with
DNA repair protein XPA and is frequently inactivated by
hypermethylation of its promoter region. p15INK4B, cyclin-
dependent kinase inhibitor 2B gene, and p14ARF (alternative
transcript of the INK4b-ARF-INK4a locus located on human
chromosome 9p21) are tumor suppressors inactivated in a
variety of cancers. p15INK4B encodes a cyclin-dependent
kinase inhibitor, whereas p14ARF functions as a stabilizer of
p53. Those genes were selected based on available informa-
tion concerning the role of their methylation in brain carcino-
genesis. In the majority of cases, gene methylation profiles
detected in free-circulating DNA reflected methylation pro-
files observed in tumor tissue samples.
Patients and methods
Patient demographics
Thirty-three newly diagnosed, previously untreated pa-
tients under the care of the Department of Neurosurgery
and Neurotraumatology at the Poznań University of
Medical Sciences were included in the study (18 men
and 15 women). Seventeen patients were diagnosed with
brain tumor of glial origin: primary or recurrent glio-
blastoma (7 patients), astrocytoma (8), or gliosarcoma
(2). The remaining 16 patients suffered from either
meningiomas (6 patients) or metastatic CNS cancer
(10). The median age was 57.9 years (ranging from 35
to 75 years). Serum samples were obtained from all
patients, while paired tumor tissue specimens were
available for 16 patients. The clinical characteristics of
the study group, including sex, age, and clinical diag-
noses, are presented in Tables 1 and 2. The research
was approved by the local Ethics Committee at the
Poznań University of Medical Sciences.
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DNA isolation
DNA from the tumor tissue was isolated using the
GeneMATRIX Tissue DNA Purification Kit (EURx,
Gdańsk, Poland), according to the manufacturer’s protocol.
Circulating tumor-derived DNA was isolated from serum
using the sodium iodide/glycogen method. Briefly, enzyme
reaction solution, containing 1.43 % SDS, 7.15 mM EDTA,
14.3 mM Tris, (pH 8.0), and Proteinase K, was added to
serum and the mixture was incubated at 56 °C for 2 h.
Subsequently, glycogen solution (Fermentas, Burlington,
Canada) was added, followed by the addition of 9M sodium
iodide and an equal volume of isopropanol. After a 15-min
incubation, the sample was centrifuged (10,000 × g for
20 min) and the pellet was washed with 45 % isopropanol
and centrifuged. Washing was repeated with 75 % ethanol.
After the final centrifugation, the pellet was dried and
dissolved in Tris-EDTA buffer. The concentration and qual-
ity of DNA samples was assessed using a NanoDrop spec-
trophotometer. The mean recovery of total DNA from 3 ml
of serum was 8.62 μg (mean concentration of 43.1 ng/μl,
with an elution volume of 200 μl).
DNA methylation analysis
The assessment of the methylation status ofMGMT, RASSF1A,
p15INK4B, and p14ARF was performed using methylation-
specific polymerase chain reaction (PCR) (Herman et al.
1996). Completely methylated control DNA (CpG Methylated
HeLa Genomic DNA, New England Biolabs, UK) and
completely unmethylated control DNA (EpiTect Control
DNA, Qiagen, Germany) served as positive and negative con-
trols, respectively. Additionally, leukocytes from healthy volun-
teers as well as a DNA sample extracted from a brain fragment
of a patient with brain hematoma served as normal control
samples for DNA methylation analysis. They showed no de-
tectable hypermethylation of the genes analyzed.
Bisulfite modification of 500 ng DNA was performed
using the EZ DNA Methylation Kit (Zymo Research,
Orange, CA, USA), following manufacturer’s instructions.
Methylation-specific PCR assay was carried out in a
MyCycler Thermal Cycler (Bio-Rad). Primer oligonucleo-
tides were obtained from Oligo.pl (Warsaw, Poland). Primer
sequences for all the analyzed genes and reaction conditions
were chosen based on previously published protocols (Dong
et al. 2005; Herman et al. 1996; Pizzi et al. 2005; Table 3).
All primer pairs were targeted towards gene promoter-
associated CpG islands. PCR reactions were carried out in
a volume of 18 μl using FastStart Taq DNA Polymerase
(Roche, Germany) as follows: after an initial step of heat
denaturation at 94 °C for 4 min, 38 cycles of 94 °C for 30 s,
appropriate annealing temperature for 30 s, and 72 °C for
45 s were carried out. Final elongation was carried out at
72 °C for 7 min. PCR products were separated by 2 %
agarose gel electrophoresis in the presence of ethidium
bromide and visualized under UV illumination.
Statistical analysis
Data were analyzed using Fisher’s exact test, with p≤0.05
being considered as statistically significant.
Results
The applied protocol of DNA isolation from serum yielded an
amount sufficient for the assessment of gene hypermethylation
in CNS cancer patients. Methylation of at least one promoter
was demonstrated in 12 out of 17 (70.58 %) serum samples
from the glial tumor group, where 5 patients had one, 6 patients
had two, and 1 patient had three promoters methylated, respec-
tively (Table 1). In this group, MGMT, RASSF1A, p15INK4B,
and p14ARF were methylated in 3/17 (17.65 %), 8/17
(47.06 %), 2/17 (11.76 %), and 7/17 (41.18 %) cases, respec-
tively. At least one promoter was methylated in the serum of 7
out of 10 metastatic CNS tumor patients and 3 out of 6
meningothelial tumor patients (Table 2).MGMTwas methylat-
ed in the circulating tumor-derived DNA from only one me-
ningioma patient, RASSF1A methylation was found in two
meningiomas and three metastatic tumors, and the methylation
of both p15INK4B and p14ARF was detected in one meningi-
oma and three metastatic tumors, respectively.
Apart from serum, samples of the corresponding tumor
tissue were available for 9 patients with glial and 7 patients
with non-glial tumors. The comparative analysis of DNA
methylation between these two sample sources is presented
in Table 4. The concordance of gene hypermethylation results
was relatively high for all the analyzed genes. Among all the
patients, 13 discordant results (20.3 %) were observed. These
were mostly false-negative cases (in respect to serum analy-
sis). Interestingly, false-positive results were observed mostly
(75 %) in the group of metastatic cancers.
No statistical differences in the frequency of gene
hypermethylation between glial and non-glial cancer patients
were found when it comes to neither serum nor tumor tissue,
except for RASSF1A. In this case, gene promoter methylation
was significantly more frequent in the samples of glial tumors
in comparison to metastatic CNS cancers (p=0.0406) (Fig. 1).
Discussion
In the past few years, much data have been gathered show-
ing that cancers of different origins release DNA into the
bloodstream (Fiegl et al. 2005; Fleischhacker and Schmidt
2007). Even though the data concerning solid tumors, such
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as lung, colon, or breast, showed the presence of tumor-
derived DNA in the blood, a limited number referred to
CNS cancers. The classical view of the brain as an isolated
environment, with the blood–brain barrier being impenetra-
ble to large molecules such as DNA, suggested possible
obstacles in finding methylation biomarkers in the blood
of those patients. However, a recent verification of this
hypothesis showed that tumor-derived DNA is present in
the serum of glioma patients and that its analysis is eligible
for biomarker purposes (Lavon et al. 2010; Wakabayashi et
al. 2009; Weaver et al. 2006). Our observations confirm the
findings that circulating tumor-derived DNA is present in
the serum of CNS cancer patients. Additionally, we verified
the utility of the sodium iodide method in yielding DNA of
appropriate quantity and quality for further methylation
detection, as suggested previously in the case of colorectal
tumors (Fong et al. 2009). Because of poor treatment out-
comes in the group of brain cancer patients, laboratory tests
based on methylation analysis of tumor-derived free-
circulating DNA may be potentially useful in patient prog-
nosis and the choice of the best suited therapy regimen
(Weaver et al. 2006).
In the present study, we analyzed the promoter methyla-
tion of MGMT, RASSF1A, p15INK4B, and p14ARF. It has
been proven that these genes play a role in the pathogenesis
of CNS cancers, where promoter hypermethylation is one of
the mechanisms of their silencing. For example, it was
suggested that p14ARF hypermethylation and MGMT
hypermethylation constitute distinct molecular pathways of
astrocytoma progression, and it is hypothesized that these
pathways could differ in biological behavior and clinical
outcome (Watanabe et al. 2007). From the diagnostic point
of view,MGMT hypermethylation is an important predictive
marker of good response to alkylating chemotherapy in GBM.
Interestingly, some reports support the thesis that serum-based
MGMT methylation analysis offers a promising alternative to
a tumor-based approach (Balańa et al. 2011). Although the
assessment of MGMT hypermethylation is a valuable marker
in the prediction of the response of GBM patients to
temozolomide treatment (Silber et al. 2012), some studies
indicate that its diagnostic performance is not satisfactory
and other methylation-based markers are proposed, e.g.,
PTEN or hMLH1 (McEllin et al. 2010; Plumb et al. 2000).
Therefore, further studies aiming at finding new relevant
markers are necessary in order to improve the effectiveness
of therapy of CNS cancer patients.
Several studies showed that serum might be a source for
circulating DNA. In contrast to plasma, serum contains
significantly higher amounts of DNA, with a low level of
contaminating extraneous DNA released from leukocytes
(Umetani et al. 2006). Thus, we first analyzed the methyla-
tion of the selected panel of genes in serum samples
obtained from patients with CNS cancers of glial or non-
glial (mostly metastatic) origin. Overall, the rate of
hypermethylation of the tested genes, besides p15INK4B,
was higher in the group of patients with tumors of glial
origin. We report frequent methylation of RASSF1A in cir-
culating tumor-derived DNA found in the serum of patients
with both primary as well as metastatic CNS tumors. This
finding is in agreement with published data, which show the
involvement of RASSF1A epigenetic silencing in CNS car-
cinogenesis (Lorente et al. 2009). When it comes to serum
RASSF1A methylation-positive cases of brain tumor pa-
tients, similar results were obtained in the study of
Dammann et al. (2005). The second gene which also
showed frequent hypermethylation in the studied patient
Table 3 Primers used in methylation-specific polymerase chain reaction (PCR) assays
Gene Primer Sequence Amplicon size Annealing temperature Reference
MGMT MF TTTCGACGTTCGTAGGTTTTCGC 81 bp 60 °C Dong et al. (2005)
MR GCACTCTTCCGAAAACGAAACG
UF TTTGTGTTTTGATGTTTGTAGGTTTTTGT 93 bp
UR AACTCCACACTCTTCCAAAAACAAAACA
RASSF1A MF GTGTTAACGCGTTGCGTATC 94 bp 60 °C Pizzi et al. (2005)
MR AACCCCGCGAACTAAAAACGA
UF TTTGGTTGGAGTGTGTTAATGTG 108 bp
UR CAAACCCCACAAACTAAAAACAA
p15INK4B MF GCGTTCGTATTTTGCGGTT 148 bp 60 °C Herman et al. (1996)
MR CGTACAATAACCGAACGACCGA
UF TGTGATGTGTTTGTATTTTGTGGTT 154 bp
UR CCATACAATAACCAAACAACCAA
p14ARF MF GTGTTAAAGGGCGGCGTAGC 122 bp 60 °C Dong et al. (2005)
MR AAAACCCTCACTCGCGACGA
UF TTTTTGGTGTTAAAGGGTGGTGTAGT 132 bp 58 °C
UR CACAAAAACCCTCACTCACAACAA
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group was p14ARF, and recent data suggest that methylation
in the promoter region of p14ARFmay be used as a biomarker
for the diagnosis of gliomas (He et al. 2011). We observed an
intermediate frequency ofMGMTmethylation in the serum of
patients with glial tumors (17.65 %), while it was low
(6.25 %) in the serum of non-glial tumor patients. The per-
centage of CNS cancer cases where methylated MGMT was
detected in the serum ranged from 20 to 50 % in other reports
(Lavon et al. 2010; Weaver et al. 2006). Finally, p15INK4B
was observed to bemethylatedwithmoderate frequency in the
serum of cancers of both glial origin (11.76 %) and in the
group consisting of non-glial tumor patients (25 %).
Of 33 serum samples under analysis, 16 had paired
frozen tissues available for assessment. The frequencies of
gene hypermethylation in tumor samples were similar to
those detected in serum with some exceptions, resulting
probably from the different number of patients in the
groups. The corresponding values were in agreement with
previously published data concerning the methylation of
MGMT (Cecener et al. 2012; Mellai et al. 2012), RASSF1A
(Dammann et al. 2005; Gao et al. 2004; Horiguchi et al.
2003), p14ARF (He et al. 2011; Nakamura et al. 2011), or
p15INK4B (Watanabe et al. 2007; Yin et al. 2002) in CNS
tumor cells, especially when taking into account the glial
tumor group. Moreover, for the first time, we propose that
RASSF1A hypermethylation may differentiate primary from
metastatic CNS cancers.
The comparison of the results obtained for paired serum
and tumor samples allowed the conclusion that the global
concordance of results between these two sample sources is
fairly high (Table 4). It is generally believed that serum-
based marker analysis shows higher specificity (which is
reflected by the rate of false-positive results) than sensitivity
(reflected by the rate of false-negative results) of detection
(Laird 2003). This assumption is confirmed also in our
studies. Thus, in general, biomarker methylation was more
frequently found in DNA from tumor than from serum,
similar to that reported by others (Board et al. 2008). Also,
in the studies of Weaver et al. (2006) and Lavon et al.
(2010), 40 to 50 % of patients were characterized by the
hypermethylation of MGMT in tumor samples, while only
half of them showed paired MGMT methylation in free-
circulating serum DNA. This can possibly be explained by
the fragmentation of circulating tumor-derived DNA.
Interestingly, most cases of false-positive gene methylation
results were detected in the group of metastatic CNS cancer
patients, while false-negative results were more frequently
found in glial tumor patients. The possible explanation of
this phenomenon is that the methylation markers detected in
the serum of metastatic tumor patients can come from DNA
originating in the primary tumor site and the metastatic cells
creating the CNS tumor may not fully reflect the DNA
methylation profile characterizing cells in the primary tumor
tissue.
Conclusions
In conclusion, our study seems to confirm the previous
findings (Lavon et al. 2010; Wakabayashi et al. 2009;
Weaver et al. 2006) that the blood–brain barrier does not
interfere significantly with the leakage of tumor-specific
DNA into the global circulation, which makes the detection
of methylation biomarkers in the serum of CNS cancer
patients possible. Gene methylation in the tumor was ac-
companied by its methylation in paired serum samples in
only half of positive cases. The sensitivity of the assay is,
therefore, not satisfactory, and further research is necessary
in order to establish a marker panel with optimal clinical
performance. The results, however, illustrate that the circu-
lating tumor-derived DNA harbors the methylation markers
found in the originating tumor tissue and is eligible for
clinical biomarker assessment. Additionally, an important
novel finding is that metastatic CNS cancers are char-
acterized by a different spectrum of epigenetic changes
than primary glial tumors, with RASSF1A hypermethylation
differentiating between these two groups. Our work
further supports the search for epigenetic CNS tumor
markers.
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